Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial.
Ali ZA, Maehara A, Généreux P, Shlofmitz RA, Fabbiocchi F, Nazif TM, Guagliumi G, Meraj PM, Alfonso F, Samady H, Akasaka T, Carlson EB, Leesar MA, Matsumura M, Ozan MO, Mintz GS, Ben-Yehuda O, Stone GW; ILUMIEN III: OPTIMIZE PCI Investigators.
Lancet. 2016 Nov 26;388(10060):2618-2628. doi: 10.1016/S0140-6736(16)31922-5. Epub 2016 Oct 30.
Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis.
Yahagi K, Kolodgie FD, Otsuka F, Finn AV, Davis HR, Joner M, Virmani R.
Nat Rev Cardiol. 2016 Feb;13(2):79-98. doi: 10.1038/nrcardio.2015.164. Epub 2015 Oct 27.
Saphenous Vein Graft Aneurysm after Drug-Eluting Stent Implantation: Treatment by Covered Stent.
Papadopoulos K, Avraamides P.
Case Rep Cardiol. 2021 Nov 5;2021:2360804. doi: 10.1155/2021/2360804. eCollection 2021.
Long-Term Results After Drug-Eluting Versus Bare-Metal Stent Implantation in Saphenous Vein Grafts: Randomized Controlled Trial.
Fahrni G, Farah A, Engstrøm T, Galatius S, Eberli F, Rickenbacher P, Conen D, Mueller C, Pfister O, Twerenbold R, Coslovsky M, Cattaneo M, Kaiser C, Mangner N, Schuler G, Pfisterer M, Möbius-Winkler S, Jeger RV; BASKET‐SAVAGE‐Investigators*.
J Am Heart Assoc. 2020 Oct 20;9(20):e017434. doi: 10.1161/JAHA.120.017434. Epub 2020 Oct 9.
Use of drug-eluting stents in saphenous vein aortocoronary bypass graft lesions: a critical appraisal.
Brilakis ES, Saeed B, Banerjee S.
J Interv Cardiol. 2008 Apr;21(2):151-7. doi: 10.1111/j.1540-8183.2007.00341.x. Epub 2008 Feb 28.
Drug-eluting Vein Graft with Acetylsalicylic Acid-Ticagrelor-Unfractionated Heparin Complex Inhibits Early Graft Thrombosis.
Akşit E, Kurt T, Büyük B, Çokkalender Ö.
Balkan Med J. 2020 Aug 11;37(5):269-275. doi: 10.4274/balkanmedj.galenos.2020.2020.1.128. Epub 2020 May 1.
Clinical outcome after surgical or percutaneous revascularization in coronary bypass graft failure.
Harskamp RE, Beijk MA, Damman P, Kuijt WJ, Woudstra P, Grundeken MJ, Kloek JJ, Tijssen JG, de Mol BA, de Winter RJ.
J Cardiovasc Med (Hagerstown). 2013 Jun;14(6):438-45. doi: 10.2459/JCM.0b013e328356a4fc.
Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial.
Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, Tiroch K, Hausleiter J, Seyfarth M, Ott I, Ibrahim T, Fusaro M, Laugwitz KL, Massberg S, Neumann FJ, Richardt G, Schömig A, Kastrati A; Is Drug-Eluting-Stenting Associated with Improved Results in Coronary Artery Bypass Grafts? (ISAR-CABG) Investigators.
Lancet. 2011 Sep 17;378(9796):1071-8. doi: 10.1016/S0140-6736(11)61255-5. Epub 2011 Aug 26.
Comparison of diagnostic accuracy of immediate angiography derived residual quantitative flow ratio after bioresorbable scaffold and drug eluting stent implantation.
Li Z, Zhan J, Han J, Fu G, Jin C.
Rev Cardiovasc Med. 2022 Feb 12;23(2):59. doi: 10.31083/j.rcm2302059.
Propensity score-matched analysis of coronary artery bypass grafting versus second-generation drug-eluting stents for triple-vessel disease.
Nishigawa K, Fukui T, Hagiya K, Tobaru T, Uemura K, Takanashi S.
Eur J Cardiothorac Surg. 2019 Jun 1;55(6):1152-1159. doi: 10.1093/ejcts/ezy415.
